Dr. Heather Jacene Appointed Chief of Molecular Imaging and Theranostics at BIDMC/HMFP Radiology

 

BIDMC/HMFP Radiology is pleased to announce that Dr. Heather Jacene will join the Department as Chief of Molecular Imaging and Theranostics on Monday, March 23, 2026.

 

Heather, an Associate Professor of Radiology at Harvard Medical School, currently serves as the Clinical Director of Nuclear Medicine at Dana-Farber Cancer Institute (DFCI) and served as the Assistant Chief of Nuclear Medicine and Molecular Imaging (NMMI) at Brigham and Women’s Hospital (BWH) from 2018-2025.

 

In these roles, Heather has overseen all administrative and procedural aspects of the daily clinical operations of Nuclear Medicine, including harmonizing practice across hospitals. She also initiated and created the multidisciplinary Theranostics service at DFCI, which was the first program to be designated as a Comprehensive Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

 

Through the SNMMI, Heather has established herself as a thought leader in the field. As Chair of the Scientific Program since 2021, she has reimagined and overseen the Society’s major meetings. In an international election of members, Heather was elected Vice President-elect in 2024 and will serve as President from 2026 to 2027.

 

From an education standpoint, Heather has trained the next generation of radiologists, nuclear medicine physicians, and molecular imaging physicians through her daily clinical role and as the Associate Program Director of the Brigham and Women’s Hospital/Harvard Medical School Joint Program in Nuclear Medicine Residency (JPNM) from 2016 to 2025.

 

From a research perspective, Heather has been immersed in the Dana-Farber/Brigham and Women’s Cancer Center NMMI oncology research portfolio, which includes between 10 and 15 active diagnostic and therapeutic clinical trials at a time.

 

We are excited to have Heather bring her strengths as an inspiring, accountable, active listener, problem-solver, and effective communicator to the role of Chief, Molecular Imaging and Theranostics, as she helps us expand the Division as part of the new DFCI collaboration.